MD3265459T2 - Compuși amidici în calitate de agoniști ai receptorilor 5-HT4 - Google Patents
Compuși amidici în calitate de agoniști ai receptorilor 5-HT4 Download PDFInfo
- Publication number
- MD3265459T2 MD3265459T2 MDE20180052T MDE20180052T MD3265459T2 MD 3265459 T2 MD3265459 T2 MD 3265459T2 MD E20180052 T MDE20180052 T MD E20180052T MD E20180052 T MDE20180052 T MD E20180052T MD 3265459 T2 MD3265459 T2 MD 3265459T2
- Authority
- MD
- Moldova
- Prior art keywords
- compounds
- receptor agonists
- amide compounds
- relates
- receptor
- Prior art date
Links
- 108091005482 5-HT4 receptors Proteins 0.000 title 1
- -1 Amide compounds Chemical class 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Prezenta invenţie se referă la compuşi cu formula (I), incluzând stereoizomerii lor şi sărurile acceptabile farmaceutic. Această invenţie se referă, de asemenea, la metode de fabricare a unor astfel de compuşi şi a compoziţiilor farmaceutice care conţin astfel de compuşi. Compuşii acestei invenţii sunt utili în tratamentul diferitelor tulburări care sunt legate de receptorul 5-hidroxitriptamină 4 (5-HT4).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN709CH2015 | 2015-02-13 | ||
| PCT/IN2016/000008 WO2016128990A1 (en) | 2015-02-13 | 2016-01-07 | Amide compounds as 5-ht4 receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MD3265459T2 true MD3265459T2 (ro) | 2019-09-30 |
Family
ID=55588327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDE20180052T MD3265459T2 (ro) | 2015-02-13 | 2016-01-07 | Compuși amidici în calitate de agoniști ai receptorilor 5-HT4 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9957257B2 (ro) |
| EP (1) | EP3265459B1 (ro) |
| JP (1) | JP6487564B2 (ro) |
| KR (1) | KR101966576B1 (ro) |
| CN (1) | CN107406434B (ro) |
| AU (1) | AU2016217461B2 (ro) |
| BR (1) | BR112017017275A2 (ro) |
| CA (1) | CA2975973C (ro) |
| CY (1) | CY1121898T1 (ro) |
| DK (1) | DK3265459T3 (ro) |
| EA (1) | EA034618B1 (ro) |
| ES (1) | ES2734734T3 (ro) |
| HR (1) | HRP20191179T1 (ro) |
| HU (1) | HUE045667T2 (ro) |
| IL (1) | IL253848B (ro) |
| LT (1) | LT3265459T (ro) |
| MA (1) | MA41633B1 (ro) |
| MD (1) | MD3265459T2 (ro) |
| ME (1) | ME03430B (ro) |
| MX (1) | MX368214B (ro) |
| NZ (1) | NZ734400A (ro) |
| PL (1) | PL3265459T3 (ro) |
| PT (1) | PT3265459T (ro) |
| RS (1) | RS59066B1 (ro) |
| SG (1) | SG11201706501VA (ro) |
| SI (1) | SI3265459T1 (ro) |
| SM (1) | SMT201900398T1 (ro) |
| TR (1) | TR201909997T4 (ro) |
| WO (1) | WO2016128990A1 (ro) |
| ZA (1) | ZA201705292B (ro) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2619829T3 (es) | 2011-11-18 | 2017-06-27 | Heptares Therapeutics Limited | Agonistas del receptor muscarínico M1 |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| GB201709652D0 (en) * | 2017-06-16 | 2017-08-02 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| CN110818661B (zh) * | 2019-12-02 | 2021-08-06 | 上海再启生物技术有限公司 | 5-ht4受体激动剂的关键中间体4-氨基-5-卤苯并呋喃-7-羧酸的制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2338882T3 (es) | 2003-11-24 | 2010-05-13 | Pfizer, Inc. | Compuestos de acido quinolona-carboxilico que tienen actividad agonista del receptor 5-ht4. |
| WO2005092882A1 (en) * | 2004-03-01 | 2005-10-06 | Pfizer Japan, Inc. | 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders |
| US8816090B2 (en) | 2005-02-25 | 2014-08-26 | Pfizer Inc. | Benzisoxazole derivatives |
| WO2007010390A1 (en) | 2005-07-22 | 2007-01-25 | Pfizer Japan Inc. | Indazolecarboxamide derivatives as 5ht4 receptor agonists |
| AR056729A1 (es) * | 2005-10-28 | 2007-10-17 | Glaxo Group Ltd | Compuesto de benzofurano carboxamida, composicion farmaceutica que lo comprende su uso para preparar un medicamento y procesos para su preparcion |
| GB0525661D0 (en) * | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Novel compounds |
| GB0603550D0 (en) | 2006-02-22 | 2006-04-05 | Glaxo Group Ltd | Novel compounds |
| CN107260736A (zh) * | 2010-02-12 | 2017-10-20 | 株式会社ＡｓｋＡｔ | 用于治疗痴呆的5‑ht4受体激动剂 |
| KR20120123089A (ko) | 2010-02-16 | 2012-11-07 | 화이자 인코포레이티드 | 5-ＨＴ₄ 수용체의 부분 효능제인 (Ｒ)-4-((4-((4-(테트라히드로푸란-3-일옥시)벤조［ｄ］이속사졸-3-일옥시)메틸)피페리딘-1-일)메틸)테트라히드로-2Ｈ-피란-4-올 |
| DK2758394T3 (en) * | 2011-09-19 | 2015-04-20 | Suven Life Sciences Ltd | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS |
| DK2976337T3 (en) * | 2013-03-20 | 2018-07-16 | Suven Life Sciences Ltd | 5-amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists |
| EA029951B1 (ru) * | 2013-12-16 | 2018-06-29 | Сувен Лайф Сайенсиз Лимитед | Соединения индазола в качестве агонистов 5-ht-рецептора |
-
2016
- 2016-01-07 CN CN201680015614.4A patent/CN107406434B/zh not_active Expired - Fee Related
- 2016-01-07 SI SI201630311T patent/SI3265459T1/sl unknown
- 2016-01-07 MX MX2017010348A patent/MX368214B/es active IP Right Grant
- 2016-01-07 EP EP16711355.4A patent/EP3265459B1/en active Active
- 2016-01-07 PL PL16711355T patent/PL3265459T3/pl unknown
- 2016-01-07 HR HRP20191179TT patent/HRP20191179T1/hr unknown
- 2016-01-07 KR KR1020177025584A patent/KR101966576B1/ko not_active Expired - Fee Related
- 2016-01-07 SG SG11201706501VA patent/SG11201706501VA/en unknown
- 2016-01-07 AU AU2016217461A patent/AU2016217461B2/en not_active Ceased
- 2016-01-07 RS RS20190836A patent/RS59066B1/sr unknown
- 2016-01-07 CA CA2975973A patent/CA2975973C/en not_active Expired - Fee Related
- 2016-01-07 WO PCT/IN2016/000008 patent/WO2016128990A1/en not_active Ceased
- 2016-01-07 DK DK16711355.4T patent/DK3265459T3/da active
- 2016-01-07 HU HUE16711355A patent/HUE045667T2/hu unknown
- 2016-01-07 NZ NZ734400A patent/NZ734400A/en not_active IP Right Cessation
- 2016-01-07 ES ES16711355T patent/ES2734734T3/es active Active
- 2016-01-07 US US15/549,663 patent/US9957257B2/en not_active Expired - Fee Related
- 2016-01-07 SM SM20190398T patent/SMT201900398T1/it unknown
- 2016-01-07 TR TR2019/09997T patent/TR201909997T4/tr unknown
- 2016-01-07 PT PT16711355T patent/PT3265459T/pt unknown
- 2016-01-07 MA MA41633A patent/MA41633B1/fr unknown
- 2016-01-07 MD MDE20180052T patent/MD3265459T2/ro not_active IP Right Cessation
- 2016-01-07 BR BR112017017275A patent/BR112017017275A2/pt not_active IP Right Cessation
- 2016-01-07 ME MEP-2019-190A patent/ME03430B/me unknown
- 2016-01-07 JP JP2017542107A patent/JP6487564B2/ja not_active Expired - Fee Related
- 2016-01-07 EA EA201791829A patent/EA034618B1/ru unknown
- 2016-01-07 LT LTEP16711355.4T patent/LT3265459T/lt unknown
-
2017
- 2017-08-04 ZA ZA2017/05292A patent/ZA201705292B/en unknown
- 2017-08-06 IL IL253848A patent/IL253848B/en active IP Right Grant
-
2019
- 2019-07-10 CY CY20191100739T patent/CY1121898T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ734400A (en) | Amide compounds as 5-ht4 receptor agonists | |
| SA518392101B1 (ar) | ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ | |
| PH12016501440A1 (en) | Novel heterocyclic compounds | |
| MD3405471T2 (ro) | Noi derivați de amoniu, procedeu pentru prepararea acestora și compoziții farmaceutice care îi conțin | |
| ATE485269T1 (de) | C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden | |
| CY1118721T1 (el) | Παραγωγα 2,3 διϋδρο-1η-ινδεν-1-υλ-2,7-διαζασπειρο[3.6]εννεανιου και η χρηση αυτων ως ανταγωνιστες ή αντιστροφοι αγωνιστες του υποδοχεα γκρελινης | |
| EA201790246A1 (ru) | Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы | |
| EA201692260A1 (ru) | Соединения 1,3,4-тиадиазола и их применение в лечении рака | |
| MD3303331T2 (ro) | Modulatori alosterici pozitivi ai receptorilor muscarinici M1 | |
| EA201790253A1 (ru) | Ингибиторы альдостеронсинтазы | |
| MX373162B (es) | Piridopirimidinonas y utilización de las mismas como moduladores de receptores de n-metil-d-aspartato (nmda). | |
| EA201691160A1 (ru) | Антагонисты s1p3 | |
| CY1116234T1 (el) | Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3 | |
| EA201791480A1 (ru) | Новые производные бензимидазола в качестве антигистаминных агентов | |
| TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
| MY195013A (en) | Tetrahydroquinoline derivatives as p2x7 receptor antagonists | |
| CY1111105T1 (el) | Ενωσεις 5-(ετεροκυκλυλ)αλκυλ-ν-(αρυλσουλφονυλ)ινδολης και η χρηση τους ως προσδεματα του 5-ητ6 | |
| MX379454B (es) | Derivados de fluoroindol como moduladores alostéricos positivos del receptor m1 muscarínico. | |
| SA521421098B1 (ar) | -h4 مركبات بيريدو بيريميدينات كمثبطات مستقبل هستامين | |
| EA201691252A1 (ru) | Соединения индазола в качестве агонистов 5-ht-рецептора | |
| CY1123185T1 (el) | Παραγωγα ινδολιου | |
| EA201650003A1 (ru) | Соединённые циклоалкилом дигетероциклические производные | |
| WO2014160143A3 (en) | Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders | |
| EA202090432A1 (ru) | Новые соединения, активирующие путь nrf2 | |
| EA202090397A1 (ru) | Фторопиперидиновые соединения в качестве чистых антагонистов 5-ht-рецептора |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent for invention definitely lapsed due to non-payment of fees |